Objective(s): This study aimed to retrospectively evaluate the toxicity and clinical outcomes in patients of locally advanced cervical cancer treated with three-dimensional conformal radiotherapy (3DCRT) and concurrent chemotherapy. tomography was performed and contouring was done according to published guidelines. External radiotherapy was followed by Intracavitary brachytherapy delivered to a dose of 9 Gy HDR in 2-fractions, given one week apart. The endpoints were treatment related toxicities and clinical outcomes. Local control (LC), overall survival (OS) and disease free survival (DFS) were evaluated and toxicities were documented using the common terminology criteria for adverse events (v3.0) (CTCAE). Results: The median follow up time was 37 (range, 19-54) months. The 3 year OS, DFS and LC were 84.2%, 80.6% and 81% respectively. Grade ≥3 acute skin, upper and lower gastrointestinal (GI) and genitourinary (GU) toxicity was observed in 3 (1.4%), 11 (5.2%), 12 (5.7%) and 0 (0%) patients, respectively. Grade ≤2 hematological toxicity was observed in 154 (73.3%) patients. Grade ≥3 late GI and GU toxicity was seen in 9 (4.2%) patients and 2 (0.9%) patients, respectively. Conclusion: 3DCRT with concurrent chemotherapy results in good loco-regional control with acceptable normal tissue toxicity. In the background of indeterminate evidence regarding routine practice of intensity modulated radiotherapy in carcinoma of the cervix, 3DCRT may be considered as the treatment of choice.
Introduction
Cervical cancer accounts for one of the commonest malignancies in females, especially in the developing countries. Concurrent chemoradiation and brachytherapy is the established standard of care treatment for locally advanced cervical cancer. Although the traditionally used conventional radiotherapy fields (4 field box technique) based on bony anatomy have resulted in fairly good loco-regional controls, but the geographic miss of the clinical target volume may often result in increased risk of failures and the large target volumes were treated results in substantial increase in gastrointestinal (GI), genitourinary (GU) and hematological toxicity (1) . On the other hand, radiotherapy techniques, i.e., Intensity Modulated Radiation Therapy (IMRT) and IMRT under image guidance (IGRT) have the distinct advantage of better target coverage without compromising the normal tissue toxicity (2) . The availability of image guidance during treatment allows for dose escalation and at the same time provides better organ sparing. However, its use in the treatment of cancer of the intact uterine cervix is not short of complexities. The significant inter and intrafraction pelvic organ motion along with the tumor regression that occurs during the treatment makes the successful outcome of these techniques challenging. The treatment delivery may be further complicated by the relatively fixed position of the pelvic lymph nodes in relation to the pelvic organ motion resulting in large shifts and the possibility of a geographical miss (3, 4) . Thus, the routine use of IMRT in radiotherapy of cancer of the intact uterine cervix continues to remain questionable and cannot be considered the standard of care. On the contrary, the less talked about 'three-dimensional conformal radiotherapy (3DCRT)' not only minimizes the risk of a geographical miss but has also shown to result in reduced gastrointestinal toxicity as compared with conventional two-dimensional techniques (5) . Although IMRT has favorably resulted in reducing the gastrointestinal toxicity compared with conventional radiotherapy, robust confirmation proving its superiority is still awaited. Meanwhile, the published evidence using 3DCRT continues to be sparse. Since the major burden of cervical cancer occurs in the less developed countries, a logistically viable, cost-effective and yet effectual treatment needs to be considered. In present era where the role of IMRT outside a clinical protocol remains yet to be established and in centers where a large number of cervical cancer patients are treated, 3DCRT may be the most reasonable option.
Keeping this background in mind an audit was conducted in our institution to evaluate the outcomes and toxicity in patients with cervical cancer treated with 3DCRT.
Materials and methods

Patient characteristics
A retrospective audit was conducted at our institution and records of 210 patients of locally advanced cervical squamous cell and adenocarcinoma treated with 3DCRT with concurrent cisplatin from January 2013 to December 2015 were analyzed in March 2018, to ensure a minimum of 2 years follow-up period for the study. Clinical staging was done using FIGO 2009 staging system. Baseline investigations like complete blood count, kidney function test, liver function test, chest Xray and viral serology were done. Cystoscopy and sigmoidoscopy were performed only in cases with clinical or radiologic suspicion of involvement of the bladder or rectum. Patients with para-aortic lymph-nodes, other histological variants and synchronous/metachronous other malignancy were excluded.
Radiotherapy planning
Simulation
Patients were kept fasting for minimum 4 h prior to planning CT scan. Oral and rectal contrast was used for delineating critical structures. Oral contrast was constituted with 20 ml urograffin dissolved in 1 litre water given over 1 hour, before CT scan. The rectal contrast was given by dissolving urograffin in 50 ml normal saline. Patients were asked to void urine 15 min prior to CT. Similar fluid intake and bladder voiding instructions were given while treating patients, to ensure a consistent and reproducible bladder filling status. After preparation, a planning CT scan was performed in the supine position with custom made foot rest as immobilization device. Anterior and lateral tattoos were marked with radio-opaque material aligned with lasers to prevent lateral rotation. Intravenous contrast, 100 ml of omnipaque was administered according to Cross method of intravenous contrast administration (6). CT scan was obtained from T10-T11 inter-space to upper third of femur, with 2.5 mm slice thickness. In patients with lower vaginal extension, a radio-opaque cervical marker was placed at the distal-most part of the involved vagina in order to ascertain the lower border of the fields. CT was acquired on the CT simulator light speed VFX-16 (GE Health Care Ltd). These images were transferred to Eclipse treatment planning system (TPS) Varian Associates, Palo Alto, CA, USA workstation. All patients were assessed for pelvic, para-aortic nodal status and metastatic involvement on planning CT before the treatment plans were made.
Contouring and planning
The contouring was done using the RTOG guidelines (7, 8) . The clinical target volume (CTV) included both the primary tumor site and regional lymphatic drainage. The primary CTV included primary gross tumor volume (GTV) with potential microscopic spread to the cervix, entire uterus, parametrium, vagina up to 3 cm below the vaginal marker and broad ligaments. The nodal CTV included the common iliac, external and internal iliac, obturator and presacral nodes. All lymph nodal groups were contoured according to the guidelines by Taylor et al. (9, 10) , the volumes were delineated by identifying contrast-enhanced pelvic blood vessels on each CT slice and using a 7 mm margin to create a 3D CTV. Total CTV (primary and nodal) was clubbed together using boolean operators. Internal target volume (ITV) uterus was contoured to account for organ motion of cervix and uterus using the expansion of 0.5 cm laterally and 1 cm in all directions. Total planning target volume (PTV) was defined as a 1 cm isotropic expansion of the total CTV. Final PTV was defined using boolean operators for ITV uterus and total PTV. Organs at risk, including the small bowel, rectum, bladder, were also contoured (10). The small bowel was delineated by contouring peritoneal cavity as a surrogate structure.
Dose prescription and chemotherapy
All the patients were treated with 3-D conformal four-field box technique using parallel opposed anteroposterior/posteroanterior and lateral fields without midline shield/block. Coverage of the final PTV was seen such that at least 95% of the final PTV received 95% of total dose with minimal dose to the normal tissues. Radiation therapy was delivered using photons generated by a 6-MV (mega voltage) or 15-MV linear accelerator. The total dose of 46 Gy in 23 fractions over 4.5 weeks was prescribed to the final PTV. Concurrent weekly Cisplatin 40 mg/m 2 administered intravenously.
Weekly hemogram & kidney function tests were performed prior to chemotherapy.
Brachytherapy
External beam radiotherapy was followed by Intracavitary brachytherapy (ICBT) delivered to a dose of 9 Gy (HDR) in two sessions given one week apart. The procedure was performed under general anesthesia and ultrasound was used to confirm the applicator position. Adequate vaginal packing was done to keep bladder and rectum away to avoid high dose to critical organs. CT based planning was done on the Oncentra planning system (Oncentra V 4.3) and administered with an Iridium-192 source (HDR v3 MicroSelectron machine, remote after loading unit). The organs at risk (OAR) namely the bladder, rectum and sigmoid were contoured. A dose of 9 Gy HDR was prescribed to point A and doses to 2cc bladder, rectum and sigmoid were recorded. The planning constraints were D2cc (minimum dose in most irradiated tissue volume measured in 2cc) rectum <75 Gy; D2cc sigmoid <75 Gy EQD2 and D2cc bladder <90 Gy EQD2, based on ABS and GEC-ESTRO guidelines. Plans were optimized whenever required.
Assessment of toxicity and follow up
Assessment of toxicity was done at every week during treatment and at the end of treatment. Toxicity was assessed according to the CTCAE (Common terminology criteria for Adverse Events) version 3.0.After treatment completion the patients were followed up every 3 months for the first 2 years and 6 months thereafter. A clinical examination was done at each follow-up visit and CT scan was done in case a recurrence was suspected.
Results
Patient characteristics
Two hundred ten patients were analyzed. Most of the patients presented with bleeding per vaginum. 
Treatment and toxicity
All patients were treated with external beam radiation followed by ICBT. The mean dose of PTV-D95 was 45.3 Gy ± 4.2 Gy. D195 (dose received by 195cc of small bowel) of small bowel averaged 43.5 Gy ± 3 Gy. Treatment interruption was seen in eight patients (range 4-14 days). All interruptions were due to Grade-3 diarrhea. The median number of chemotherapy cycles received were 4(range 2-5). Forty-four patients experienced interruptions in chemotherapy administration. Twenty-six patients had chemotherapy interruptions due to low total leukocyte count (TLC), four due to low hemoglobin, four due to both low TLC and thrombocytopenia and another 10 had interrupted chemotherapy due to Grade-2 diarrhea and poor compliance. Most of the patients had Grade-1 or 2 acute toxicities. Acute Grade ≥3 skin, vomiting, and lower gastrointestinal (GI) toxicity were observed in 3 (1.4%), 11 (5.2%) and 12 (5.7%) patients, respectively. Grade-1 and Grade-2 hematological toxicity was seen in 113 (53.8%) and 41(19.5%) patients, respectively. Only 3(1.4%) patients had Grade-3 hematological toxicity. Late GI Grade ≥3 toxicity was seen in only 9 (4.2%) patients and 2 (0.9%) had late GU toxicity (Table 2) .
Outcomes
At a median follow up of 37 months (range, 19-54 months), 170 (81%) patients were clinically disease-free. Ten (4.8%) patients had local residual disease at last follow up. Of the overall 30 relapses, 20 (66.7%) patients had distant metastasis, 2 (6.6%) had nodal failures and 8 (26.7%) had local relapses. Age, hemoglobin, tumor size and pelvic node involvement proved to be significant prognostic factors for local control. Disease-free survival (DFS) was calculated as presence or absence of local/nodal/metastatic disease at the last follow-up or at death. Overall survival (OS) was calculated from the date of diagnosis to the date of last follow up or death. DFS and OS was 80.6% and 84.2%, respectively, in our study. Presence of pelvic lymph nodes and tumor size adversely affected the DFS. Pelvic lymph nodes and tumor size more than 4 cm were also proved to be important prognostic factors affecting overall survival (Figs 1 and 2) ( Table 3 ).
Discussion
The cervical cancer treatment has evolved over years. After the National Cancer Institute (NCI) clinical alert in 1999, concurrent chemoradiation became treatment of choice for cervical cancer (11, 12) . Radiotherapy given concurrently with weekly cisplatin 40 mg/m 2 is the standard treatment for locally advanced cervical carcinoma. Since concurrent chemoradiation was established as the standard of care, radiotherapy techniques have evolved from conventional 2-Dimensional planning to 3-DCRT and IMRT. Conventional 2D planning based on bony landmarks results in the inclusion of the entire pelvis within the radiation portals resulting in higher doses to bladder, rectum and small bowel. Since the introduction of CT in the early 1990s, CT based 3-Dimensional planning has gained fame because of its ability to better spare doses to the organ at risk (OARs) (with the use of multi-leaf collimators), computerized dosimetry and better treatment accuracy. Early results from Gerstner et al. (5) . showed decreased incidences of GI toxicities with the use of 3DCRT. Importantly, 20% of patients treated with the standard4-field box technique had a geographic miss at the cervix. Similar results were established by Gulia et al. (13) . in which the median V95 for conventional and modified 4-field plans (CT-based delineation) were observed to be 89.4% and 93%, respectively, means an inadequate target volume coverage with conventional 4-field box technique. 3DCRT has also been shown to improve overall survival when compared with 2D conventional Radiotherapy (14) , although the analysis was a retrospective population-based study.
Radiotherapy along with radio-sensitizing chemotherapy has improved the local control and overall survival in comparison with radiotherapy alone, but it has also increased the treatment related toxicity (15) . Around 45%of intact cervical cancer patients undergoing chemoradiation experience acute gastrointestinal toxicity (≥Grade 2) and approximately one-sixth of patients report genitourinary toxicity (≥Grade 2) (1). With advancements in treatment came the IMRT technique, the use of which was reported early this century by Mundt et al. (2) . They showed that IMRT significantly improved conformity and decreased doses to the OARs when compared with conventional whole pelvic radiotherapy. The clinical results showed reduction of gastrointestinal (P = 0.001) and genitourinary toxicities (P = 0.38). Since then, the use of IMRT was extensively studied. Gandhi et al. (16) , has compared the toxicities and outcomes in patients with locally advanced carcinoma cervix, treated with whole pelvic four-field conventional radiotherapy or whole pelvic IMRT. Their results showed that IMRT resulted in lower rates of gastrointestinal toxicity and comparable clinical outcomes than did conventional radiotherapy. Reduced doses to the pelvic bone marrow with the use of IMRT have been shown to result in reduced incidences of neutropenia and subsequent treatment breaks. Apart from the acute toxicities, incidences of chronic gastrointestinal and genitourinary toxicities have also been shown to be reduced with the use of IMRT (17) . The advantages of IMRT can thus be summarized as dosimetric (reduction in doses to the OARs, dose escalation, improved conformity, ability to achieve concave dose distributions) and the clinical decrease in treatment-related toxicities meant better compliance to treatment and thereby improved outcomes. One important caveat is that almost all studies which have attempted to reduce the toxicities using IMRT have compared their results with conventional 4-field box technique. Only one randomized study till date has compared 3DCRT and IMRT techniques in intact cervical cancer patients. Twenty patients each were randomized into two arms, 3DCRT and IMRT. Patients in both arms received concurrent chemoradiation (cisplatin 40 mg/m 2 weekly; 50 Gy/25 fractions/5 weeks). Except for gastrointestinal toxicities and higher grade genitourinary toxicity, other toxicities were comparable between the two groups. Significant reduction of Grade 2 or more (20% vs 45%; P = 0.058) and Grade ≥3 (5% vs 15%, P = 0.004) acute genitourinary toxicity and Grade ≥2 (20% vs 45%, P = 0.003) and Grade ≥3 (5% vs. 20%, P = 0.004) acute gastrointestinal toxicity while no significant difference for Grade 2 and 3 or more hematological toxicity was noted in patients treated with IMRT compared to 3DCRT (18) . Similar studies have been conducted in post-op patients of carcinoma cervix (PARCER (19) and TIME-C (20) trials). The results of both studies have been conflicting, with the TIME-C trial showing a benefit in the reduction of short-term bowel and bladder toxicities with the use of IMRT, and the PARCER trial negating any such benefit of IMRT over 3DCRT. The incidences of early and late toxicities in our study were comparable to that reported in the above studies. Acute Grade ≥3 upper and lower gastrointestinal toxicities were observed in 11(5.2%) and 12(5.7%) patients, Grade ≤2 hematological toxicity in 73.3%, and late GU & GI Grade ≥3 were 0.9% and 4.2% patients, respectively, in our study. Acute and chronic gastrointestinal and genitourinary toxicities of different study groups were compared with our data in Table 4 . Loco-regional control rate in our study was 81% after a median follow-up period of 37 months. In the multicentric 'INTERTECC-2' trial treating patients with IMRT, 2-year progression-free survival and overall survival for patients were 78.6% and 90.8%, respectively (21). Gandhi et al. (16) has reported similar 2-year DFS and OS of 60% and 85.7% respectively, in the WP-IMRT group, which was not significantly different to the conventional WPRT group (79.4% DFS and 76% OS). Our study reported 3-year DFS and OS of 80.6% and 84.2%, respectively, which is comparable to these studies. Also, 20 patients (9.5%) experienced distant metastasis which is similar to 12.5% reported in the 'INTERTECC-2' trial. In the present study CECT was done whenever recurrence was suspected which may underestimate the progression-free survival in asymptomatic patients with metastatic disease.
Previous retrospective data and randomized trials have showed significant reduction in acute and late GI and GU toxicity with IMRT. But survival advantage with the use of IMRT technique has not been established by comparing IMRT with either conventional 4-field box technique or with the use of 3DCRT (22, 23) . IMRT has thus not become the standard of care in gynecological malignancies. Despite the advantages, IMRT is a double-edged sword not free from demerits -IMRT process involves complex treatment planning -image acquisition using approved institutional protocols, meticulous target delineation, cumbersome planning process and verification, all of which are time-consuming and labor intensive, both for the patient and the health care providers. Also, image guidance is mandatory to ensure the accuracy of treatment delivery, without which there is a high risk of geographical miss of the target volumes.
Though minimizing acute toxicities is important to improve patient compliance and treatment outcomes, chronic (late) toxicities significantly impair quality of life and remain the cause of long term morbidity. The incidence of acute toxicities is primarily determined by the quality of External beam Radiotherapy and the incidence of late toxicities is primarily determined by the quality of brachytherapy. Use of conformal technique for EBRT and CT or MRI planning for image based brachytherapy shall form ideal combination for cervical cancer treatment.
Conclusion
In developing countries most of the patients belong to lower socioeconomic status and present in locally advanced stages. Treating (22) Prospective
Cervix IA -IVB IMRT (n = 135) 50.4 Gy/1.8 Gy Gd ≥3 = 6% (GI+ GU) Non-IMRT (n = 317) 50.4 Gy/1.8 Gy Gd3≥ = 17% (GI + GU) P value 0.0017 Du XL et al. 2012 (23) Prospective N = 122
Cervix IIB-III B RF-IMRT (n = 60) 61.5 Gy Gd ≥ 3 = 5.3% Gd ≥ 3 = 7.1% Gd ≤ 2 = 43.9% Gd ≤ 2 = 28.1% Gd ≥ 3 = 0% Gd ≥ 3 = 0% Conventional (n = 62) 45-55 Gy Gd ≥ 3 = 10% Gd ≥ 3 = 18.3% Gd ≤ 2 = 48.3% Gd ≤ 2 = 36.6% Gd ≥ 3 = 18.4%
Gd ≥ 3 = 15% P value 0.03 0.001 0.017 0.044 Gandhi et al. 2013 (16) Prospective N = 44
Cervix IIB-III B WP-IMRT (n = 22) 50.4 Gy/1.8 Gy Gd ≥ 2 = 31.8% Gd ≥ 2 = 23.8% Overall = 13.6% Gd ≥ 3 = 4.5% Gd ≥ 3 = 0% Conventional 4-field box (n = 22) 50.4 Gy/1.8 Gy Gd ≥ 2 = 63.6% Gd ≥ 2 = 31.8% Overall = 50% Gd ≥ 3 = 27.3% Gd ≥ 3 = 13.6% P value 0.03(Gd ≥ 2) 0.4 (Gd ≥ 2) 0.011 0.04(Gd ≥ 3) 0.12(Gd ≥ 3) Present study Retrospective N = 210
Cervix II-III 3D-CRT 46 Gy/2 Gy Gd ≤ 2 = 68% Gd ≤ 2 = 33.8% Gd ≤ 2 = 35.2% Gd ≤ 2 = 20.9% Gd ≥ 3 = 5.7%
Gd ≥ 3 = 0% Gd ≥ 3 = 4.2% Gd ≥ 3 = 0.9%
Gd, Grade; IM-WPRT, intensity modulated whole pelvic radiation therapy; IMRT, intensity modulated radiation therapy; RF-IMRT, reduced field intensity modulated radiation therapy; WP-IMRT, Whole pelvic intensity modulated radiation therapy; 3D CRT, 3-dimensional conformal radiation therapy.
such patients requires a technique of radiotherapy which is less toxic without compromising survival. Though IMRT would be the preferred technique in an ideal scenario, the high incidence, cost burden, long waiting lists and the complexity involving the procedure make it a less suitable option in the health institutes where high volumes of patients are to be treated per day. 3DCRT is an ideal modality in such situations which bridges the gap between the conventional box technique and IMRT, with toxicities not significantly higher than the IMRT technique and without compromising the survival outcomes. The background of our study is based on the realization of the same. In the absence of robust evidence, the toxicity and survival results of our study serve as a proof of evidence that 3DCRT may be the preferred radiotherapy technique in developing countries.
